Barclays lowered the firm’s price target on Twist Bioscience to $55 from $60 and keeps an Overweight rating on the shares. The company’s gross margins are on track to hit 50% in 2025, but the question remains on potential upside, the analyst tells investors in a research note. The firm believes management is gaining visibility with top accounts on more blanket orders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- TWST Earnings this Week: How Will it Perform?
- Twist Bioscience says first patient dosed in Pure Biologics’ BA-0405 study
- Twist Bioscience announces launch of CHO Express Antibodies
- Twist Bioscience launches synthetic RNA control for H5N1 Influenza A
- Twist Bioscience price target raised to $60 from $45 at Barclays